[144] Arcutis Biotherapeutics, Inc. SEC Filing
Form 144 notice for Arcutis Biotherapeutics, Inc. (ARQT): The filing reports a proposed sale of 36,130 common shares through Merrill (Columbus, OH), with an aggregate market value of $583,716.00, against total outstanding shares of 119,905,078. The approximate date of sale is listed as 09/04/2025 on the NASDAQ. The filing documents the acquisition history for the securities to be sold, showing multiple employer stock purchase plan purchases and restricted stock vesting events between 03/01/2023 and 05/31/2024 totaling the lots listed. The filing also discloses a prior sale by Masaru Matsuda of 6,330 common shares on 08/04/2025 for gross proceeds of $90,687.00. The filer affirms no undisclosed material adverse information.
Avviso Form 144 per Arcutis Biotherapeutics, Inc. (ARQT): La comunicazione segnala la proposta vendita di 36.130 azioni ordinarie tramite Merrill (Columbus, OH), per un valore di mercato complessivo di $583.716,00, su un totale di 119.905.078 azioni in circolazione. La data approssimativa della vendita 猫 indicata come 09/04/2025 su NASDAQ. Il documento riporta la storia delle acquisizioni delle azioni da vendere, evidenziando pi霉 acquisti tramite piani aziendali di acquisto azioni e eventi di maturazione di azioni vincolate tra il 01/03/2023 e il 31/05/2024 che compongono i lotti elencati. Viene inoltre divulgata una vendita precedente da parte di Masaru Matsuda di 6.330 azioni ordinarie il 04/08/2025 per proventi lordi di $90.687,00. Il dichiarante afferma l'assenza di informazioni materiali avverse non divulgate.
Aviso Formulario 144 para Arcutis Biotherapeutics, Inc. (ARQT): La presentaci贸n informa la propuesta venta de 36.130 acciones ordinarias a trav茅s de Merrill (Columbus, OH), con un valor de mercado agregado de $583.716,00, sobre un total de 119.905.078 acciones en circulaci贸n. La fecha aproximada de la venta figura como 09/04/2025 en NASDAQ. El expediente documenta el historial de adquisici贸n de los t铆tulos a vender, mostrando m煤ltiples compras mediante planes de compra de acciones de empleados y eventos de consolidaci贸n de acciones restringidas entre el 01/03/2023 y el 31/05/2024 que suman los lotes indicados. Tambi茅n se revela una venta previa por Masaru Matsuda de 6.330 acciones ordinarias el 04/08/2025 por ingresos brutos de $90.687,00. El declarante afirma que no existen informaciones adversas materiales no divulgadas.
Form 144 韱奠 鈥� Arcutis Biotherapeutics, Inc. (ARQT): 鞝滌稖 靹滊鞐� 霐半ゴ氅� Merrill(旖滊熂氩勳姢, OH)毳� 韱淀暣 36,130 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜鞎§潃 $583,716.00鞚搓碃 氚滍枆欤检嫕 齑濎垬電� 119,905,078鞛呺媹雼�. 鞓堨爼 毵り皝鞚检潃 NASDAQ鞐� 09/04/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 靹滊電� 毵る弰 雽�靸� 歃濌秾鞚� 旆摑 雮挫棴鞚� 氍胳劀頇旐晿鞐�, 03/01/2023攵赌韯� 05/31/2024 靷澊鞐� 鞚措（鞏挫 鞐煬 彀鞚� 歆侅洂 欤检嫕 毵れ瀰 瓿勴殟瓿� 鞝滍暅欤� 頃挫(vest) 靷贝霌れ潉 韱淀暣 氇呾嫓霅� 搿滍姼霌れ澊 順曥劚霅橃棃鞚岇潉 氤挫棳欷嶋媹雼�. 霕愴暅 Masaru Matsuda臧� 08/04/2025鞐� 6,330 氤错喌欤茧ゼ 毵る弰頃橃棳 齑濎垬鞚� $90,687.00毳� 鞏混潃 靷嫟霃� 瓿奠嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞛愲姅 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 頇曥柛頃╇媹雼�.
Avis Formulaire 144 pour Arcutis Biotherapeutics, Inc. (ARQT) : le d茅p么t signale la vente propos茅e de 36听130 actions ordinaires via Merrill (Columbus, OH), pour une valeur marchande agr茅g茅e de $583听716,00, sur un total de 119听905听078 actions en circulation. La date approximative de vente est indiqu茅e comme 09/04/2025 sur le NASDAQ. Le dossier documente l'historique d'acquisition des titres 脿 vendre, montrant plusieurs achats dans le cadre de plans d'achat d'actions pour employ茅s et des 茅v茅nements d'acquisition de titres restreints entre le 01/03/2023 et le 31/05/2024 qui composent les lots list茅s. Le d茅p么t divulgue 茅galement une vente ant茅rieure par Masaru Matsuda de 6听330 actions ordinaires le 04/08/2025 pour un produit brut de $90听687,00. Le d茅clarant affirme qu'il n'existe pas d'informations d茅favorables mat茅rielles non divulgu茅es.
Form 144-Mitteilung f眉r Arcutis Biotherapeutics, Inc. (ARQT): Die Einreichung meldet einen geplanten Verkauf von 36.130 Stammaktien 眉ber Merrill (Columbus, OH) mit einem Gesamtmarktwert von $583.716,00 bei insgesamt 119.905.078 ausstehenden Aktien. Das ungef盲hre Verkaufsdatum ist auf der NASDAQ mit 09/04/2025 angegeben. Die Unterlagen dokumentieren die Erwerbshistorie der zu verkaufenden Wertpapiere und zeigen mehrere K盲ufe im Rahmen von Mitarbeiteraktienkaufpl盲nen sowie Vesting-Ereignisse eingeschr盲nkter Aktien zwischen dem 01/03/2023 und 31/05/2024, die die aufgef眉hrten Lose bilden. Ferner wird ein fr眉herer Verkauf durch Masaru Matsuda von 6.330 Stammaktien am 04/08/2025 f眉r Bruttoerl枚se von $90.687,00 offengelegt. Der Einreicher versichert, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
- Transparent disclosure of a proposed insider sale (36,130 shares, $583,716) consistent with Rule 144 requirements
- Detailed acquisition history included (ESPP purchases and restricted stock vesting dates and amounts)
- Insider sale activity may be interpreted negatively by some investors: proposed sale of 36,130 shares and a prior sale of 6,330 shares on 08/04/2025
Insights
TL;DR: Routine insider sale notice; materiality is limited but important for transparency.
The Form 144 documents a proposed sale of 36,130 Arcutis common shares valued at $583,716 and shows acquisition via ESPP and restricted stock vesting. Such filings are required to comply with Rule 144 and provide market participants visibility into insider liquidity. The prior sale of 6,330 shares for $90,687 is recorded, indicating recent disposal activity by the same seller. There are no earnings figures, debt changes, or corporate actions disclosed in this notice; its primary investor implication is disclosure of insider share movement rather than a change to company fundamentals.
TL;DR: Compliance-focused filing showing insider sales and acquisition history; no governance issues asserted.
The filing lists the sources of the shares鈥擡Mployer stock purchase plan and multiple restricted stock vesting dates鈥攄emonstrating that the securities originated from compensated equity awards and purchases. The signer attests there is no undisclosed material adverse information. This Form 144 is a compliance disclosure and does not allege or reveal governance changes, executive departures, or policy amendments. Its significance lies in transparent reporting of insider selling activity.
Avviso Form 144 per Arcutis Biotherapeutics, Inc. (ARQT): La comunicazione segnala la proposta vendita di 36.130 azioni ordinarie tramite Merrill (Columbus, OH), per un valore di mercato complessivo di $583.716,00, su un totale di 119.905.078 azioni in circolazione. La data approssimativa della vendita 猫 indicata come 09/04/2025 su NASDAQ. Il documento riporta la storia delle acquisizioni delle azioni da vendere, evidenziando pi霉 acquisti tramite piani aziendali di acquisto azioni e eventi di maturazione di azioni vincolate tra il 01/03/2023 e il 31/05/2024 che compongono i lotti elencati. Viene inoltre divulgata una vendita precedente da parte di Masaru Matsuda di 6.330 azioni ordinarie il 04/08/2025 per proventi lordi di $90.687,00. Il dichiarante afferma l'assenza di informazioni materiali avverse non divulgate.
Aviso Formulario 144 para Arcutis Biotherapeutics, Inc. (ARQT): La presentaci贸n informa la propuesta venta de 36.130 acciones ordinarias a trav茅s de Merrill (Columbus, OH), con un valor de mercado agregado de $583.716,00, sobre un total de 119.905.078 acciones en circulaci贸n. La fecha aproximada de la venta figura como 09/04/2025 en NASDAQ. El expediente documenta el historial de adquisici贸n de los t铆tulos a vender, mostrando m煤ltiples compras mediante planes de compra de acciones de empleados y eventos de consolidaci贸n de acciones restringidas entre el 01/03/2023 y el 31/05/2024 que suman los lotes indicados. Tambi茅n se revela una venta previa por Masaru Matsuda de 6.330 acciones ordinarias el 04/08/2025 por ingresos brutos de $90.687,00. El declarante afirma que no existen informaciones adversas materiales no divulgadas.
Form 144 韱奠 鈥� Arcutis Biotherapeutics, Inc. (ARQT): 鞝滌稖 靹滊鞐� 霐半ゴ氅� Merrill(旖滊熂氩勳姢, OH)毳� 韱淀暣 36,130 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞚措┌, 齑� 鞁滉皜鞎§潃 $583,716.00鞚搓碃 氚滍枆欤检嫕 齑濎垬電� 119,905,078鞛呺媹雼�. 鞓堨爼 毵り皝鞚检潃 NASDAQ鞐� 09/04/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 靹滊電� 毵る弰 雽�靸� 歃濌秾鞚� 旆摑 雮挫棴鞚� 氍胳劀頇旐晿鞐�, 03/01/2023攵赌韯� 05/31/2024 靷澊鞐� 鞚措（鞏挫 鞐煬 彀鞚� 歆侅洂 欤检嫕 毵れ瀰 瓿勴殟瓿� 鞝滍暅欤� 頃挫(vest) 靷贝霌れ潉 韱淀暣 氇呾嫓霅� 搿滍姼霌れ澊 順曥劚霅橃棃鞚岇潉 氤挫棳欷嶋媹雼�. 霕愴暅 Masaru Matsuda臧� 08/04/2025鞐� 6,330 氤错喌欤茧ゼ 毵る弰頃橃棳 齑濎垬鞚� $90,687.00毳� 鞏混潃 靷嫟霃� 瓿奠嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞛愲姅 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 頇曥柛頃╇媹雼�.
Avis Formulaire 144 pour Arcutis Biotherapeutics, Inc. (ARQT) : le d茅p么t signale la vente propos茅e de 36听130 actions ordinaires via Merrill (Columbus, OH), pour une valeur marchande agr茅g茅e de $583听716,00, sur un total de 119听905听078 actions en circulation. La date approximative de vente est indiqu茅e comme 09/04/2025 sur le NASDAQ. Le dossier documente l'historique d'acquisition des titres 脿 vendre, montrant plusieurs achats dans le cadre de plans d'achat d'actions pour employ茅s et des 茅v茅nements d'acquisition de titres restreints entre le 01/03/2023 et le 31/05/2024 qui composent les lots list茅s. Le d茅p么t divulgue 茅galement une vente ant茅rieure par Masaru Matsuda de 6听330 actions ordinaires le 04/08/2025 pour un produit brut de $90听687,00. Le d茅clarant affirme qu'il n'existe pas d'informations d茅favorables mat茅rielles non divulgu茅es.
Form 144-Mitteilung f眉r Arcutis Biotherapeutics, Inc. (ARQT): Die Einreichung meldet einen geplanten Verkauf von 36.130 Stammaktien 眉ber Merrill (Columbus, OH) mit einem Gesamtmarktwert von $583.716,00 bei insgesamt 119.905.078 ausstehenden Aktien. Das ungef盲hre Verkaufsdatum ist auf der NASDAQ mit 09/04/2025 angegeben. Die Unterlagen dokumentieren die Erwerbshistorie der zu verkaufenden Wertpapiere und zeigen mehrere K盲ufe im Rahmen von Mitarbeiteraktienkaufpl盲nen sowie Vesting-Ereignisse eingeschr盲nkter Aktien zwischen dem 01/03/2023 und 31/05/2024, die die aufgef眉hrten Lose bilden. Ferner wird ein fr眉herer Verkauf durch Masaru Matsuda von 6.330 Stammaktien am 04/08/2025 f眉r Bruttoerl枚se von $90.687,00 offengelegt. Der Einreicher versichert, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen.
FAQ
What does the Form 144 filed for ARQT disclose?
Who sold shares recently according to the filing?
What is the source of the shares to be sold?
What is the total number of Arcutis shares outstanding noted in the filing?
Which broker is handling the proposed sale?
